Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment.
Abstract
Remnant lipoproteins such as chylomicron and very low density lipoprotein (VLDL) remnants have been implicated in the progression of coronary atherosclerosis. Recently, a novel method for the determination of the remnant-like lipoprotein particle cholesterol (RLP-C) concentration was developed based on immunoaffinity-separation of plasma. The compositional characteristics of RLP are strikingly similar to those of postprandially modified VLDL. In addition, the method also detects chylomicron remnants. We investigated the relationship between the plasma RLP-C concentration and the angiographic outcome of the 2-year, randomised, placebo-controlled Lipid Coronary Angiography Trial (LOCAT), which used gemfibrozil as lipid lowering agent. The RLP-C response to gemfibrozil treatment has not been described before. Gemfibrozil reduced the median RLP-C concentration by 34%. The on-treatment RLP-C concentration was significantly associated with the progression of the minimum lumen diameter (MLD) (P<0.004). The plasma levels of RLP-C as well as the change in response to treatment was closely associated with plasma triglycerides and the association between on-treatment RLP-C concentration and progression of MLD was not independent of plasma triglycerides. A significant relation was seen between RLP-C and the occurrence of new lesions in vein grafts. Subjects with one new lesion had an approximately 25% higher on-treatment RLP-C concentration and the four patients showing two new lesions had a 100% higher RLP-C concentration than patients without vein graft stenosis. A total of 19 out of 23 subjects having one new lesion, and all four patients showing two new lesions, were assigned to the placebo group. We conclude that the RLP-C concentration, which is likely to reflect the plasma cholesterol contained in postprandially modified VLDL and chylomicron remnants, is strongly associated with angiographically verified progression of focal coronary atherosclerosis, and that lowering of RLPs prevents vein graft stenosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Remnants have been identified within human atherosclerosis plaques.
“Remnants have been identified within human atherosclerosis plaques (145).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [145]
Cites
Plasma triglyceride and coronary heart disease
Austin, M. A. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.2 · Cited by 697 · see citing works
Postprandial lipoproteins and progression of coronary atherosclerosis
Karpe, F., Steiner, G. A., Uffelman, K. D., Olivecrona, T., & Hamsten, A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90085-x · Cited by 486 · see citing works
Self-citationEricsson, C.-G., Fairé, U. D., Grip, L., Svane, B., Hamsten, A., & Nilsson, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91343-4 · Cited by 438 · see citing works
&NA; (1996) · The Endocrinologist · doi:10.1097/00019616-199609000-00019 · Cited by 417 · see citing works
Frick, M., Syvänne, M., Nieminen, M., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y., Pasternack, A., & Taskinen, M. R. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 409 · see citing works
PHILLIPS, N. R., Waters, D. D., & Havel, R. J. (1993) · Circulation · doi:10.1161/01.cir.88.6.2762 · Cited by 345 · see citing works
Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321 · see citing works
Kugiyama, K., Doi, H., Takazoe, K., Kawano, H., Soejima, H., Mizuno, Y., Tsunoda, R., Sakamoto, T., Nakano, T., Nakajima, K., et al. (1999) · Circulation · doi:10.1161/01.cir.99.22.2858 · Cited by 284 · see citing works
Phillips, A. N., & Smith, G. D. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90155-3 · Cited by 275 · see citing works
Campos, E. M., Nakajima, K., Tanaka, A., & Havel, R. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41527-5 · Cited by 185 · see citing works
Alaupovic, P., Mack, W. J., Knight‐Gibson, C., & Hodis, H. N. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.4.715 · Cited by 184 · see citing works
Ruotolo, G., Ericsson, C.-G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J. Å., Fairé, U. D., & Hamsten, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00442-2 · Cited by 158 · see citing works
Self-citationRemnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation
Doi, H., Kugiyama, K., Ohgushi, M., Sugiyama, S., Matsumura, T., Ohta, Y., Nakano, T., Nakajima, K., & Yasue, H. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00291-8 · Cited by 121 · see citing works
Leary, E. T., Wang, T., Baker, D. J., Cilla, D. D., Zhong, J., Warnick, G. R., Nakajima, K., & Havel, R. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.12.2490 · Cited by 110 · see citing works
Devaraj, S., Vega, G., Lange, R., Grundy, S. M., & Jialal, I. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00089-8 · Cited by 94 · see citing works
Takeichi, S., Yukawa, N., Nakajima, Y., Osawa, M., Saito, T., Seto, Y., Nakano, T., Saniabadi, A. R., Adachi, M., Wang, T., et al. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00246-9 · Cited by 79 · see citing works
Syvänne, M., Nieminen, M. S., Frick, M. H., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., Ehnholm, C., & Taskinen, M. (1998) · Circulation · doi:10.1161/01.cir.98.19.1993 · Cited by 67 · see citing works
Sakata, K., Miho, N., Shirotani, M., Yoshida, H., Takada, Y., & Takada, A. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00209-8 · Cited by 62 · see citing works
Marcoux, C., Tremblay, M., Nakajima, K., Davignon, J., & Cohn, J. S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32142-8 · Cited by 61 · see citing works
Marcoux, C., Tremblay, M., Fredenrich, A., Jacques, H., Krimbou, L., Nakajima, K., Davignon, J., & Cohn, J. S. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00042-2 · Cited by 57 · see citing works
Masuoka, H., Ishikura, K., Kamei, S., Obe, T., Seko, T., Okuda, K., Koyabu, S., Tsuneoka, K., Tamai, T., Sugawa, M., et al. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.89586 · Cited by 33 · see citing works
Syvänne, M., Taskinen, M., Nieminen, M. S., Manninen, V., Kesäniemi, Y., Pasternack, A., Nawrocki, J., Haber, H., & Frick, M. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00091-8 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works
“Remnants have been identified within human atherosclerosis plaques (145).”
Twickler, T. B., Dallinga-Thie, G. M., Cohn, J. S., & Chapman, M. J. (2004) · Circulation · doi:10.1161/01.cir.0000125278.58527.f3 · Cited by 201 · see citing works
Lai, C.-Q., Demissie, S., Cupples, L. A., Zhu, Y., Adiconis, X., Parnell, L. D., Corella, D., & Ordovas, J. M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400192-jlr200 · Cited by 163 · see citing works
Stalenhoef, A. F., & de Graaf, J. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328304b63c · Cited by 121 · see citing works
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50 · see citing works
- Authors
- Karpe, F.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Karpe, F
- ORCID
- Karpe, F
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 157
- Issue
- 1
- Pages
- 181-187
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2042894344
- Cited by
- 50
- References
- 22
- Citations by year
- 2023: 1 · 2018: 3 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 4
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Aarne Koskelon Säätiö
- Otsuka America
- Vetenskapsrådet
- Sydäntutkimussäätiö
- Otsuka Pharmaceutical
- Marcus och Amalia Wallenbergs minnesfond
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- gemfibrozil, coronary atherosclerosis progression, vein graft stenosis, chylomicron remnants, plasma triglycerides, minimal lumen diameter, angiographic outcomes, lipid-lowering therapy
- MeSH terms
- Hypolipidemic Agents, Apolipoproteins, Cholesterol, Constriction, Pathologic, Coronary Artery Disease, Double-Blind Method, Humans, Lipoproteins, Triglycerides, Veins, Gemfibrozil
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
